Johnson & Johnson (NYSE:JNJ) is set to kick off the second quarter pharma earnings on Wednesday, with investors focusing on the drugmaker’s guidance amid U.S. President Donald Trump’s ongoing threats to impose tariffs on the sector.

Net income: $15.3 million, or $0.86 per diluted share (GAAP) in Q2 2025; adjusted to $16.6 million, or $0.94 per diluted share, excluding M&A and debt extinguishment costs, in Q2 2025.

China's economy slowed in the second quarter but bucked expectations of a larger slowdown in the face of U.S. tariffs, a property market slump and a sluggish global economy, official figures out Tuesday show.

GAC has shared in the losses of its Japanese partners, Honda and Toyota, which have ceded market share in China to local brands such as BYD. Sales of GAC's Aion- and Trumpchi-branded EV and plug-in hybrid cars have also weakened amid intense competition.

State Street reports strong Q2 results with cost controls and asset inflows but faces pricing pressures. Click here to read my most recent analysis of STT.

Investors will closely monitor the company's performance against ongoing challenges, such as macroeconomic pressures and tariff

China's smartphone shipments dropped by 4.0% Y/Y in the second quarter, the International Data Corporation (IDC) said on Tuesday.

EV sales dipped 6.3% as buyers awaited tax credit changes, with GM gaining share and used EV sales reaching a new record.

For traders who focus on events, examining the historical reactions of the stock to earnings announcements can offer useful insights.

S&P 500 EPS growth is expected to come in at 4.8% for Q2, which would be the lowest growth rate since Q4 2023.